These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33039279)

  • 21. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
    Martínez GJ; Celermajer DS; Patel S
    Atherosclerosis; 2018 Feb; 269():262-271. PubMed ID: 29352570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?
    Whayne TF
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):1-10. PubMed ID: 32356107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Antiatherosclerotic Therapies.
    Libby P; Everett BM
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):538-545. PubMed ID: 30816799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD; Aday AW; Rose LM; Ridker PM
    Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Colchicine in Acute Coronary Syndromes.
    Vaidya K; Martínez G; Patel S
    Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy.
    Kaplan RC; Frishman WH
    Heart Dis; 2001; 3(5):326-32. PubMed ID: 11975814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine.
    Andreotti F; Maggioni AP; Campeggi A; Iervolino A; Scambia G; Massetti M
    Eur Heart J Suppl; 2021 Oct; 23(Suppl E):E13-E18. PubMed ID: 34650351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
    Ruscica M; Ferri N; Macchi C; Corsini A; Sirtori CR
    Ann Med; 2018 Sep; 50(6):461-484. PubMed ID: 29976096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition.
    Satish M; Agrawal DK
    Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
    Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
    J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice.
    Avan A; Tavakoly Sany SB; Ghayour-Mobarhan M; Rahimi HR; Tajfard M; Ferns G
    J Cell Physiol; 2018 Nov; 233(11):8508-8525. PubMed ID: 29932219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-inflammatory therapies for cardiovascular disease.
    Ridker PM; Lüscher TF
    Eur Heart J; 2014 Jul; 35(27):1782-91. PubMed ID: 24864079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
    Grebe A; Hoss F; Latz E
    Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
    Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies.
    Sun M; Dubé MP; Hennessy T; Schultz CJ; Barhdadi A; Rhainds D; Hillis GS; Tardif JC
    Int J Cardiol; 2022 Sep; 363():20-22. PubMed ID: 35716932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
    Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
    N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP?
    Ridker PM
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1222-4. PubMed ID: 18565847
    [No Abstract]   [Full Text] [Related]  

  • 40. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.